Experienced in Aase Syndrome

Dr. Paul M. Szabolcs

Pediatric Hematology Oncology
2100 Erwin Rd, 
Durham, NC 
Clinical Trials:Currently Recruiting for 1 Trial
35 Years of Experience
Experienced in Aase Syndrome
2100 Erwin Rd, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Szabolcs is a Pediatric Hematologist Oncology provider in Durham, North Carolina. Dr. Szabolcs has been practicing medicine for over 35 years and is rated as an Experienced provider by MediFind in the treatment of Aase Syndrome. His top areas of expertise are Graft Versus Host Disease (GvHD), Severe Combined Immunodeficiency (SCID), Systemic Sclerosis (SSc), Leukemia, and Bone Marrow Transplant.

His clinical research consists of co-authoring 34 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, he has co-authored 1 article and participated in 1 clinical trial in the study of Aase Syndrome.

Specialties
Pediatric Hematology Oncology
Licenses
Pediatric Hematology-Oncology in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Cigna
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
UPMC
  • EPO
  • PPO

Locations

2100 Erwin Rd, Durham, NC 27710

Additional Areas of Focus

Dr. Szabolcs has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Immune Thrombocytopenic Purpura (ITP)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults ≤55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation
Enrollment Status: Recruiting
Publish Date: December 15, 2025
Intervention Type: Drug
Study Drugs: Hydroxyurea, Alemtuzumab, Fludarabine, Melphalan, Thiotepa
Study Phase: Phase 2
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
A Randomized Trial of Low Versus Moderate Exposure Busulfan for Infants With Severe Combined Immunodeficiency (SCID) Receiving TCRαβ+/CD19+ Depleted Transplantation: A Phase II Study by the Primary Immune Deficiency Treatment Consortium (PIDTC) and Pediatric Blood and Marrow Transplant Consortium (PBMTC)
Enrollment Status: Active_not_recruiting
Publish Date: February 03, 2026
Intervention Type: Drug, Device
Study Drug: Busulfan
Study Phase: Phase 2
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA Matched Cadaveric Donors (RTB-003)
Bilateral Orthotopic Lung Transplant in Tandem With CD3+ and CD19+ Cell Depleted Bone Marrow Transplant From Partially HLA Matched Cadaveric Donors (RTB-003)
Enrollment Status: Completed
Publish Date: July 22, 2025
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies
Enrollment Status: Completed
Publish Date: April 06, 2025
Intervention Type: Drug, Other
Study Drug: Omidubicel
Study Phase: Phase 3
View 3 Less Clinical Trials

34 Total Publications

Prophylactic high-dose granulocyte transfusions following allogeneic haematopoietic stem cell transplantation.
Prophylactic high-dose granulocyte transfusions following allogeneic haematopoietic stem cell transplantation.
Journal: Vox sanguinis
Published: February 04, 2025
Similar Doctors
Experienced in Aase Syndrome
Dr. Kris M. Mahadeo
Pediatric Hematology Oncology
Experienced in Aase Syndrome
Dr. Kris M. Mahadeo
Pediatric Hematology Oncology

Duke Health Integrated Practice Inc

2301 Erwin Rd, 
Durham, NC 
 (0.2 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances

Kris Mahadeo is a Pediatric Hematologist Oncology provider in Durham, North Carolina. Dr. Mahadeo is rated as an Advanced provider by MediFind in the treatment of Aase Syndrome. His top areas of expertise are Hepatic Venoocclusive Disease with Immunodeficiency, Leukemia, Infantile Neutropenia, Bone Marrow Transplant, and Bone Graft.

Experienced in Aase Syndrome
Dr. Alexandra Borst
Pediatric Hematology Oncology
Experienced in Aase Syndrome
Dr. Alexandra Borst
Pediatric Hematology Oncology

University Of North Carolina At Chapel Hill

101 Manning Dr, 
Chapel Hill, NC 
 (9.8 miles away)
984-974-1000
Languages Spoken:
English
See accepted insurances

Alexandra Borst is a Pediatric Hematologist Oncology provider in Chapel Hill, North Carolina. Dr. Borst is rated as an Advanced provider by MediFind in the treatment of Aase Syndrome. Her top areas of expertise are Arteriovenous Malformation, Sickle Cell Disease, Hemoglobin SC Disease, Thalassemia, and Spinal Fusion.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Szabolcs's expertise for a condition
ConditionClose
    View All 14 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile